Kymab is discovering and developing fully human monoclonal antibody therapeutics using their pioneering Kymouse™ platform. They are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

They are improving the value of Kymouse platform still further for therapeutic antibody and vaccine discovery through novel developments.

Their strategy is to use their pioneering technology to grow their in-house drug discovery and development pipeline, as well as partner with others to maximise the technology's application in the development of novel medicines.

They have a highly experienced leadership team and Board of Directors who have proven track records of successfully developing marketed therapeutic biologics and growing billion dollar companies.

Their team has a rich mix of relevant scientific and business experience from many of the world's leading biotechnology, pharmaceutical and academic organisations.

Since their founding in 2010, they have secured $220 million in equity financing from leading investors to enable us to develop the Kymouse platform and create a portfolio of therapeutic antibody assets. With private financing from Wellcome Trust, Bill & Melinda Gates Foundation, Woodford Patient Capital Trust plc, Malin Corporation plc, ORI Fund and Hepalink, they can create a mature and long-term vision for success in tackling some of the most challenging diseases.

They have leveraged technology developed in the laboratory of Professor Allan Bradley from the Sanger Institute, a world leading genomics research centre.